anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The extensor digitorum profundus complex underwent degeneration of the ulnar segments during primate adaptation and evolution. This process resulted in the preservation of only the extensor pollicis longus and extensor indicis in some apes, including humans. Consequently, anatomical variations within the digitorum profundus complex in modern humans have been well-documented, with detailed reports on their frequency and patterns in previous studies. Here, we report an unusual arrangement involving two anomalies in the extensor digitorum profundus complex, identified in a 66-year-old Japanese male cadaver. In this cadaver, two accessory muscles differentiated from both the extensor pollicis longus and extensor indicis. Notably, the latter muscle featured a tendon bifurcating towards both the thumb and index fingers, referred to as the extensor pollicis et indicis communis. Under the extensor retinaculum, the tendon of the accessory extensor pollicis longus passed through an independent compartment, whereas that of the extensor pollicis et indicis communis traversed a compartment shared by the extensor indicis and the extensor digitorum communis. Both muscles were innervated by the posterior interosseous nerve. Previous studies have reported that the accessory slip of the extensor pollicis longus and extensor pollicis et indicis communis appear at frequencies of 0.6% and 0.4-1.4%, respectively. However, to the best of our knowledge, a configuration in which both appear simultaneously has not been reported. The data from this case could provide essential insights into the variations in the extensor digitorum profundus complex in humans and non-human primates.
Photodynamic therapy (PDT) involves the i.v. injection of Photofrin followed by the illumination of the tumor using a fiber optic device. Two days after the injection, a laser light (180 J/cm(2)) will be applied to the tumor. A second light application will be given 96-120 hours after Photofrin injection if PDT could not initially be performed on all sides of the tumor. Post illumination, all patients will undergo stenting as part of standard medical care procedure. Up to 3 additional courses of PDT using a light dose of 120 J/cm(2) may be given at 3-month intervals. Standard Medical Care (SMC) is defined as stenting procedure plus chemotherapy regimen.
Klebsiella pneumoniae is among the most important Gram-negative pathogens that can cause serious nosocomial infections. The emergence and prevalence of hypervirulent carbapenem-resistant K. pneumoniae (Hv-CRKP) pose a significant challenge to public health. In this study, we characterized thirty carbapenem-resistant K. pneumoniae (CRKP) strains from a tertiary care hospital in Sichuan province, China, by whole-genome sequencing and genome analysis. These strains were all highly resistant to carbapenem but remained susceptible to tigecycline. Of the 30 tested CRKP strains, 23 were positive for blaKPC-2 and seven for blaNDM-5. These blaKPC-2-positive strains all belonged to ST11, while blaNDM-5-positive strains belonged to five distinct STs. Phylogenetic analysis revealed a predominant intra-hospital transmission of ST11-KL64 in KPC-2-producing CRKP, and that both clonal and horizontal transmission of blaNDM-5 have occurred among NDM-5-producing CRKP strains in this hospital. Hypervirulence genes were commonly detected in the CRKP. The prevalent pLVKP-like plasmid and ICEKp seem to have contributed largely to the transmission of virulence genes in them. blaNDM-5 was located on highly similar IncX3 plasmids in the collected strains, and its truncated vision was highlighted. blaKPC-2 was primarily carried by IncFII/IncR plasmids in our collection. At least two IncFII/IncR plasmid subtypes were identified, exhibiting high similarity to many previously reported blaKPC-2-bearing plasmids from different parts of China. The findings provide an expanded knowledge of the genetic characteristics of CRKP, the transmission pattern of carbapenem-resistance genes, and also the convergence of Hv-CRKP.
The implant pockets will be debrided with the Labrida BioClean™ biodegradable brush for 2 minutes and with the brush seated in an oscillating dental handpiece (NSK ESQ10 TEQ) and thereafter irrigated with sterile saline. The treatment will be repeated every three months. Debridement is performed with local anaesthesia as needed.
Human-to-human contact plays a leading role in the transmission of infectious diseases, and the contact pattern between individuals has an important influence on the intensity and trend of disease transmission. In this paper, we define regular contacts and random contacts. Then, taking the COVID-19 outbreak in Yangzhou City, China as an example, we consider age heterogeneity, household structure and two contact patterns to establish discrete dynamic models with switching between daytime and nighttime to depict the transmission mechanism of COVID-19 in population. We studied the changes in the reproduction number with different age groups and household sizes at different stages. The effects of the proportion of two contacts patterns on reproduction number were also studied. Furthermore, taking the final size, the peak value of infected individuals in community and the peak value of quarantine infected individuals and nucleic acid test positive individuals as indicators, we evaluate the impact of the number of random contacts, the duration of the free transmission stage and summer vacation on the spread of the disease. The results show that a series of prevention and control measures taken by the Chinese government in response to the epidemic situation are reasonable and effective, and the young and middle-aged adults (aged 18-59) with household size of 6 have the strongest transmission ability. In addition, the results also indicate that increasing the proportion of random contact is beneficial to the control of the infectious disease in the phase with interventions. This work enriches the content of infectious disease modeling and provides theoretical guidance for the prevention and control of follow-up major infectious diseases.
A process for producing a pretreated feedstock is provided. The feedstock is selected from grasses, cereal straws, stover, and combinations thereof, and least about 80% of the feedstock has a particle length of between about 2 cm and about 40 cm. This process comprises wetting the feedstock in liquid, pressing the wet feedstock through one roll press or a series of roll presses to remove at least a portion of water and soluble substances from the wetted feedstock and to shear the feedstock to produce feedstock particles of a size suitable for pumping at a solids concentration of about 8% to about 20% when slurried. At least one roll press, or at least one roll press in the series of roll presses comprises rolls with circumferential v-shaped grooves. The pressed feedstock particles are slurried to produce a slurried feedstock having a consistency of between about 8% and about 20%, and the slurried feedstock pumped into a pretreatment reactor. Dilute acid pretreatment of the slurried feedstock is carried out at a temperature of 160° C. to 280° C.
PROBLEM TO BE SOLVED: To obtain a preventive and therapeutic agent having autoreactive T-cell inhibitory activities by making the agent include immunoglobulin as an active ingredient. SOLUTION: This preventive and therapeutic agent contains an immunoglobulin, preferably of a chemically unmodified type [natural, hardly having modification and change, decrease of antibody titer and decrease of antibody spectrum, and having anticomplementary action (complement fixation properties) sufficiently lower than 20 units (CH-50 value)] as an active ingredient. The preparation is preferably administered by intravenous administration, and the daily dose is 100-1,000 mg/kg body weight and preferably intravenously administered as an everyday medication of one to several days. The immunoglobulin is preferably the one derived from human, and a polyethylene glycol-treated human immunoglobulin is preferably used.  The immunoglobulin is useful for prevention and treatment of myositis associated with autoreactive T-cell (e.g. the myositis associated with the T-cell, reactive with a skeletal muscle myosin of oneself).
Strategies to prevent or delay Alzheimer's disease and related dementias (AD/ADRD) are urgently needed, and blood pressure (BP) management is a promising strategy. Yet the effects of different BP control strategies across the life course on AD/ADRD are unknown. Randomized trials may be infeasible due to prolonged follow-up and large sample sizes. Simulation analysis is a practical approach to estimating these effects using the best available existing data. However, existing simulation frameworks cannot estimate the effects of BP control on both dementia and cardiovascular disease. This manuscript describes the design principles, implementation details, and population-level validation of a novel population-health microsimulation framework, the MIchigan ChROnic Disease SIMulation (MICROSIM), for The Effect of Lower Blood Pressure over the Life Course on Late-life Cognition in Blacks, Hispanics, and Whites (BP-COG) study of the effect of BP levels over the life course on dementia and cardiovascular disease. MICROSIM is an agent-based Monte Carlo simulation designed using computer programming best practices. MICROSIM estimates annual vascular risk factor levels and transition probabilities in all-cause dementia, stroke, myocardial infarction, and mortality in a nationally representative sample of US adults 18+ using the National Health and Nutrition Examination Survey (NHANES). MICROSIM models changes in risk factors over time, cognition and dementia using changes from a pooled dataset of individual participant data from 6 US prospective cardiovascular cohort studies. Cardiovascular risks were estimated using a widely used risk model and BP treatment effects were derived from meta-analyses of randomized trials. MICROSIM is an extensible, open-source framework designed to estimate the population-level impact of different BP management strategies and reproduces US population-level estimates of BP and other vascular risk factors levels, their change over time, and incident all-cause dementia, stroke, myocardial infarction, and mortality.
The amount of fentanyl released from each system per hour is proportional to the surface area (25 mcg/hr per 6.25 cm2). The composition per unit area of all system sizes is identical.

Fentanyl transdermal system is a translucent rectangular patch with rounded corners comprising a protective liner and two functional layers. Proceeding from the outer surface toward the surface adhering to skin, these layers are: 

1) a backing layer of polyolefin film; and 2) a drug-in-adhesive layer. Before use, a protective liner covering the adhesive layer is removed and discarded.

Fentanyl transdermal systems are packaged with additional pieces of protective film above and below the system within each pouch. These are also discarded at the time of use.

The active component of the system is fentanyl. The remaining components are pharmacologically inactive.
OBJECTIVE: Few reports discuss the characteristics of repeated recidivism of cholesteatoma. We describe the clinical characteristics of patients with cholesteatoma who experienced at least two recidivism episodes after initial surgery for cholesteatoma requiring canal wall reconstruction.
METHODS: We reviewed the medical records of 11 patients who underwent surgery for cholesteatoma with canal wall reconstruction at our department between April 2008 and March 2018 and subsequently experienced two relapses that necessitated revision surgery involving tympanomastoidectomy with canal reconstruction. Patient age at the time of the first surgery ranged from 6 to 56 (mean, 25.7) years. Seven (63.6%) of the 11 patients were male. These 11 patients were classified according to the type of recidivism, and their characteristics (pathology, operation date, operation method, pattern of relapse, and position of recurrence) were investigated.
RESULTS: Four cases involved secondary residual cholesteatoma, with the mean interval between the first revision surgery and the second revision surgery being 23.8 (range, 11-39) months. Secondary residual sites included the anterior tympanic cavity, tympanic sinus, and anterior end of the reconstructed cartilage of the canal wall. The other seven cases involved secondary recurrence, with the mean interval between the first and the second revision surgery being 26.1 (range, 12-57) months. The sites of recurrence were at the edges of the reconstructed cartilage. One notable case involved the cartilage junction, leading us to hypothesize that retraction of the temporal muscle flap and the patulous Eustachian tube was the underlying cause.
CONCLUSION: For residual cholesteatoma, strict measures are necessary to maintain the operation under clear view, and more careful follow-up is necessary in patients who have had previous surgery at another hospital. For recurrent cholesteatoma, it was recognized that Eustachian tube function must be ascertained in advance, and careful observation of the reconstructed cartilage edge is necessary.
The present invention relates to alginic sodium diester for freeze-dried injection. The present invention contains alginic sodium diester and excipient vehicles (sodium chloride, mannitol, dextran 40, etc.). Every 1000 bottles contain 25 to 200g of alginic sodium diester, and 200 to 25g of excipient vehicle according to weight proportion. The present invention is made into freeze-dried pharmaceutical preparation by advanced low-temperature freeze-drying technology, namely that the present invention overcomes the disadvantage of low biological availability of tablet type products, and overcomes the disadvantages of discoloration and instability in the storage life of injecta type products due to high-temperature sterilization. The present invention is stable in storage life, and is suitable for clinical application. The present invention has the functions of lowering blood viscosity, resisting blood coagulation, reducing blood fat, improving microcirculation, etc., is used for preventing and curing ischemic heart and brain angiopathy and hyperlipemia, and has the advantages of stable performance, high safety, high reliability, convenient clinical operation, etc.
DNA topoisomerase II alpha (TOP2A) expression, gene alterations, and enzyme activity have been studied in various malignant tumors. Abnormal elevation of TOP2A expression is considered to be related to the development of non-small cell lung cancer (NSCLC). However, its association with tumor metastasis and its mode of action remains unclear. Bioinformatics, real-time quantitative PCR, immunohistochemistry and immunoblotting were used to detect TOP2A expression in NSCLC tissues and cells. Cell migration and invasion assays as well as cytoskeletal staining were performed to analyze the effects of TOP2A on the motility, migration and invasion ability of NSCLC cells. Cell cycle and apoptosis assays were used to verify the effects of TOP2A on apoptosis as well as cycle distribution in NSCLC. TOP2A expression was considerably upregulated in NSCLC and significantly correlated with tumor metastasis and the occurrence of epithelial-mesenchymal transition (EMT) in NSCLC. Additionally, by interacting with the classical ligand Wnt3a, TOP2A may trigger the canonical Wnt signaling pathway in NSCLC. These observations suggest that TOP2A promotes EMT in NSCLC by activating the Wnt/β-catenin signaling pathway and positively regulates malignant events in NSCLC, in addition to its significant association with tumor metastasis. TOP2A promotes the metastasis of NSCLC by stimulating the canonical Wnt signaling pathway and inducing EMT. This study further elucidates the mechanism of action of TOP2A, suggesting that it might be a potential therapeutic target for anti-metastatic therapy.
PURPOSE:To obtain the titled composition having improved tissue-target property to specific organ especially lung and liver by the enzymatic activity in the organ of living body, by adding a drug to a small sphere of a mixture of a hydrogenated phospholipid and a polyhydric alcohol fatty acid ester. CONSTITUTION:For example, a hydrogenated phospholipid and a polyhydric alcohol fatty acid ester are dissolved in a solution produced by dissolving a drug in an organic solvent. The solvent is distilled off to form coarse granular substance, which is dispersed in hot water. The dispersion is cooled, centrifuged and freeze-dried to obtain the titled composition. It has excellent biocompatibility and drug absorptivity. When the small sphere reaches an organ having high enzymatic activity of internal organ of living body, especially lipase activity, rapid decomposition of the polyhydric alcohol fatty acid ester takes place to release the contained drug (e.g. antitumor agent, agent for hepatopathy, etc.) at the site. It has remarkable target effect especially for lung and liver.
No in vivo clinical trials have investigated the effect of ARICEPT on the clearance of drugs metabolized by CYP 3A4 (e.g. cisapride, terfenadine) or by CYP 2D6 (e.g. imipramine). However, in vitro studies show a low rate of binding to these enzymes (mean Ki about 50-130 μM), that, given the therapeutic plasma concentrations of donepezil (164 nM), indicates little likelihood of interference.

Whether ARICEPT has any potential for enzyme induction is not known. Formal pharmacokinetic studies evaluated the potential of ARICEPT for interaction with theophylline, cimetidine, warfarin, digoxin and ketoconazole. No effects of ARICEPT on the pharmacokinetics of these drugs were observed.
The present invention relates to a method for producing an aqueous dispersion of an inorganic UV blocking agent, and a cosmetic composition including the same. More specifically, the method comprises: a pre-dispersing step of adding an inorganic UV blocking agent in a dispersion agent and a dispersion medium mixed solution, and agitating and wetting by an agi-mixer; and a dispersing step of dispersing only wetted aqueous dispersion by using a continuous bead mill device of 0.05-5 mm. The inorganic UV blocking agent is titanium dioxide, zinc oxide, or a mixture thereof. The dispersion agent is polyglyceryl-4caprate. The dispersion medium is refined water. According to the present invention, disadvantages such as using sensation and white turbidity occurring when titanium dioxide or zinc oxide is used as a hydrophilic-type cosmetic material such as BB cream, sun care, foundation, and white cream can be overcome. Moreover, when dispersion of titanium dioxide or zinc oxide according to the present invention is contained in a cosmetic composition, UV blocking effects, stability, and usability are excellently ensured.
This study is a research project examining the effects of noninvasive brain stimulation on anxiety. This study will help us to better understand possible treatments for patients diagnosed with anxiety disorders. Participants will undergo a functional magnetic resonance imaging (fMRI) and a computed tomography (CT) scan, to image the bone and brain tissue. Participants will receive noninvasive brain stimulation using low-intensity focused ultrasound (LIFU) sound waves, to temporarily change brain activity. Participants will undergo a threat task involving brief (100ms) shocks (1-5mA) and startle noises. Brain signals (EEG), muscle twitch (EMG), heart rate and rhythm, blood pressure, respiration rate, and skin moisture will be monitored throughout. Participants will be asked to complete behavioral questionnaires.
HIV-1 RNA emerges in CSF early in the course of HIV disease. Studies have shown that high levels of HIV-1 RNA in CSF correlate with increased severity of dementia and worsened performance on neuropsychological tests. While combination antiretroviral treatments are potent suppressors of HIV-1 replication in plasma, the extent to which these treatments suppress viral replication in CSF is unknown. A few studies suggest that antiretroviral treatments can reduce HIV-1 RNA in CSF. However, since CSF is isolated from peripheral immune responses to HIV and antiretroviral treatment may not readily penetrate the compartment, researchers hypothesize the remaining virus will overcome the antiretroviral treatment to achieve high levels of viral replication again. This virologic failure is likely accompanied by decreased cognitive function. It is therefore critical to determine the ability of antiretroviral treatments to control HIV-1 replication in the CSF and the durability of that viral suppression.

Patients enrolling in one of several AACTG-sponsored potent antiretroviral therapy trials (a "parent" trial) may enter this study. \[AS PER AMENDMENT 06/06/00: Patients already enrolled in an AACTG-sponsored study who are changing treatment due to virologic failure may also enter this study.\] \[AS PER AMENDMENT 11/15/01: Patients starting a new potent antiretroviral regimen as part of their clinical care, enrolling in a potent antiretroviral treatment trial, or changing potent antiretroviral therapy in clinical care or in an ongoing antiretroviral treatment trial because of virologic failure may enter this study.\] Patients receive no treatment but undergo various procedures aimed at characterizing the effects of antiretroviral therapies on CSF viral load and cognitive function. Procedures include: 1) venipuncture to measure plasma HIV-1 RNA and DNA levels, CD4+ T cell count, and cytokine and immune activation markers associated with HIV-1 neurological disorders; 2) neuropsychological examinations to measure cognitive function; and 3) lumbar punctures to obtain CSF samples, which are used to determine the pharmacokinetics of antiretroviral agents in CSF and to determine levels of blood cells, cytokine and immune activation markers, and HIV-1 RNA and DNA. An entry visit must occur before initiating potent antiretroviral therapy in the parent trial \[AS PER AMENDMENT 06/06/00: or before changing the antiretroviral regimen due to virologic failure in an ongoing trial\]. \[AS PER AMENDMENT 11/15/01: Patients are registered before initiating a new potent antiretroviral regimen.\] Subsequent visits occur within 21 days prior to each lumbar puncture and at Weeks 24 and 52. If evaluations, procedures, or assays for a given patient's parent trial \[AS PER AMENDMENT 11/15/01: for any coenrollment AACTG study\] occur at the times specified in this study, they are not duplicated for this study. Other visits may occur when a patient changes antiretroviral treatment or discontinues a parent trial \[AS PER AMENDMENT 11/15/01: discontinues a potent antiretroviral therapy\].
— In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean C and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%. No information is available about the interaction of cephalexin and metformin following multiple doses of either drug. Metforminmax

Although not observed in this study, adverse effects could potentially arise from co¬administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems. Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.

— As with other β-lactams, the renal excretion of cephalexin is inhibited by probenecid. Probenecid
Patients receive azacitidine 40mg/m2 subcutaneously (SQ) on days 1-6 and 8-10 and entinostat 7mg PO on days 3 and 10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.